[et_pb_section fb_built=”1″ next_background_color=”#ffffff” _builder_version=”4.27.4″ _module_preset=”default” use_background_color_gradient=”on” background_color_gradient_stops=”#001970 0%|#303f9f 100%” bottom_divider_style=”wave2″ bottom_divider_height=”50px” bottom_divider_height_tablet=”50px” bottom_divider_height_phone=”25px” bottom_divider_height_last_edited=”on|phone” da_disable_devices=”off|off|off” locked=”off” global_colors_info=”{}” da_is_popup=”off” da_exit_intent=”off” da_has_close=”on” da_alt_close=”off” da_dark_close=”off” da_not_modal=”on” da_is_singular=”off” da_with_loader=”off” da_has_shadow=”on”][et_pb_row _builder_version=”4.27.4″ _module_preset=”default” custom_margin=”0px||||false|false” custom_padding=”0px||||false|false” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][dipi_dual_heading first_heading=”A\/Prof Olalekan O. Oluwole” second_heading=”Associate Professor of Medicine, Vanderbilt-Ingram Cancer Center” heading_display=”column” _builder_version=”4.27.4″ _module_preset=”default” first_heading_font=”|700|||||||” first_heading_text_color=”#ffffff” first_heading_font_size=”40px” second_heading_text_color=”#E8EAF6″ hover_enabled=”0″ first_heading_font_size_tablet=”40px” first_heading_font_size_phone=”30px” first_heading_font_size_last_edited=”on|phone” second_heading_font_size_tablet=”” second_heading_font_size_phone=”” second_heading_font_size_last_edited=”on|phone” global_colors_info=”{}” sticky_enabled=”0″][\/dipi_dual_heading][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ _builder_version=”4.27.4″ _module_preset=”default” da_disable_devices=”off|off|off” locked=”off” global_colors_info=”{}” da_is_popup=”off” da_exit_intent=”off” da_has_close=”on” da_alt_close=”off” da_dark_close=”off” da_not_modal=”on” da_is_singular=”off” da_with_loader=”off” da_has_shadow=”on”][et_pb_row column_structure=”1_4,3_4″ use_custom_gutter=”on” gutter_width=”2″ _builder_version=”4.27.4″ _module_preset=”default” custom_margin=”0px||0px||true|false” custom_padding=”0px||0px||true|false” global_colors_info=”{}”][et_pb_column type=”1_4″ _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_image src=”https:\/\/meeting.anztct.org.au\/2025\/wp-content\/uploads\/sites\/4\/2025\/04\/anztct-2025-olalekan-oluwole-500px.jpg” alt=”Olalekan Oluwole” title_text=”Olalekan Oluwole” _builder_version=”4.27.4″ _module_preset=”default” border_radii=”on|50%|50%|50%|50%” border_width_all=”5px” border_color_all=”#303F9F” global_colors_info=”{}”][\/et_pb_image][\/et_pb_column][et_pb_column type=”3_4″ _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][dipi_dual_heading first_heading=”Keynote” second_heading=”About A\/Prof Olalekan O. Oluwole” heading_display=”column” fh_style=”background” first_heading_color=”#E8EAF6″ _builder_version=”4.27.4″ _module_preset=”default” first_heading_font=”|||on|||||” first_heading_font_size=”11px” first_heading_letter_spacing=”1px” text_orientation=”left” custom_margin=”||10px||false|false” custom_padding=”||0px||false|false” hover_enabled=”0″ global_colors_info=”{}” sticky_enabled=”0″][\/dipi_dual_heading][et_pb_text _builder_version=”4.27.4″ _module_preset=”default” hover_enabled=”0″ global_colors_info=”{}” sticky_enabled=”0″]A\/Prof Olalekan O. Oluwole specializes in the treatment of hematological malignancies using stem cell transplantation and cellular therapy. He founded the Vanderbilt-Ingram Cancer Center (VICC) cellular therapy research program, and designed the nascent Vanderbilt initiative to expand cell therapy as an institution-wide resource for malignant and non-malignant disorders.<\/p>\n
His primary field of research is in improving the safety profile of cellular therapy through investigator-initiated intervention trials, multi-institution sponsored therapeutic research and national consortium outcomes research. He led sponsored research showing the benefit of prophylactic corticosteroids during chimeric antigen receptor (CAR) T cell treatment and led a coalition of experts to publish a reference guide for outpatient CAR-T therapy. He is deeply invested in community engagement efforts to safely transition CAR-T to the outpatient setting. He is very active in the American Society for Transplant and Cell Therapy (ASTCT) where he is a member of the board of directors. He is a member of many committees including of the ASTCT Committee on Cellular Therapy and Committee on Practice Guidelines. He is board certified in internal medicine, hematology and medical oncology.[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section]<\/p>\n","protected":false},"excerpt":{"rendered":"
Associate Professor of Medicine, Vanderbilt-Ingram Cancer Center<\/p>\n","protected":false},"author":8,"featured_media":229,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_et_pb_use_builder":"on","_et_pb_old_content":"","_et_gb_content_width":"2880","footnotes":""},"categories":[10],"tags":[],"dipi_cpt_category":[],"class_list":["post-267","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-keynote"],"yoast_head":"\n